ABSTRACT In a group of 39 patients who received fibrinolytic therapy for acute myocardial infarction, serum crosslinked fibrin degradation products (XLDP) were quantitated by an enzymelinked immunosorbent assay (ELISA) using an antibody reactive with a site near the yy crosslink of fibrin, and characterized by a gel electrophoretic method to distinguish fibrinogen degradation products (FDP) from XLDP. After coronary artery reperfusion, 63 of 81 (69%) serum samples showed XLDP by gel analysis, whereas the incidence of positive samples before reperfusion, 53 of 144 (37%), was significantly less (p < .0001). The first appearance of serum XLDP by gel analysis was most often in the 15 min interval immediately before or after angiographic documentation of reperfusion, and the elapsed treatment time required to produce a positive test was shorter with more intensive treatment regimens. However, the appearance of serum XLDP was not a specific indicator of reperfusion in individual patients, since one or more serum samples was positive in five of eight patients who did not show reperfusion as well as in 27 of 29 patients who did show reperfusion. Furthermore, the concentration of serum XLDP as measured by ELISA showed no significant difference in samples from patients who did or did not have reperfusion or between samples taken before or after reperfusion. There was a close temporal correlation between the first appearance of serum XLDP (gel analysis) and the initial decrease in plasma fibrinogen (systemic lytic state), and the degree of elevation of serum XLDP (ELISA) was also correlated with the intensity of the systemic lytic state. In addition, electrophoretic analysis of pretreatment plasma samples demonstrated crosslinked fibrin polymers that disappeared during fibrinolytic therapy coincident with the appearance of serum XLDP and in parallel with fibrinogen conversion to degradation products (fragments X, Y, and D). Two patients without a lytic state showed no change in plasma fibrin polymers during therapy, and XLDP were not present in serum despite coronary reperfusion in one patient. Thus the results indicate that XLDP appearing in the blood during fibrinolytic therapy for acute myocardial infarction are not predictive of successful fibrinolytic therapy, but rather may reflect degradation of circulating fibrin polymers associated with the fibrinogenolysis of the systemic lytic state.
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Methods
Blood samples. Blood was collected before therapy and at 15 min intervals during catheterization from the femoral artery catheter (after discarding the first 10 ml) or from a peripheral vein into sodium citrate (0.4% final concentration) and c-aminocaproic acid (EACA) (0. 1 M final concentration). Plasma was separated from red cells by centrifugation of blood at 3500 g for 15 min at 40 C. To prepare serum, blood was collected into thrombin (10 U/ml final concentration) and EACA (0. 1M final concentration) and allowed to clot for 1 hour at 370 C, then centrifuged as for plasma. To determine whether the EACA was effective in inhibiting proteolysis during serum preparation, streptokinase at concentrations up to 500 U/ml was added to blood containing 0. 1M EACA and serum was prepared. Gel analysis of these samples showed no XLDP and no FDP corresponding to fragments X, Y, or D. Fibrinogen concentration was determined as clottable protein by the method of Ratnoff and Menzie.27 A "systemic lytic state" was defined as a decrease in plasma fibrinogen of 10% or more. Plasma and serum were stored at -200 C prior to testing. Plasma and serum samples were obtained from patients with acute myocardial infarction who were treated with fibrinolytic therapy; the selection crite- ATotal dose 32,000 to 534,000 U over 67 to 130 min.
B30 mg as a 5 min intravenous bolus.
Cinitial therapy with a 5 min intravenous bolus of APSAC, 5 to 30 mg, followed after 16 to 64 min by intracoronary streptokinase at a total dose of 40,000 to 194,000 U over 6 to 56 min.
in the serum before treatment. After 12 min of therapy, bands corresponding to both FDP and XLDP were present and these increased in intensity throughout the course of therapy. A systemic lytic state was evident by the time of the 12 min sample with a fall of plasma fibrinogen to 49% of original concentration, coincident with the appearance in serum of fibrinogen fragments X, Y, and D. Reperfusion was documented by angiography at 90 min. The concentration of XLDP measured by ELISA was below the sensitivity of the assay in the pretreatment sample, increased to a peak of 1220 ng/ml at 40 min, then decreased to between 400 and 700 ng/ml until the last sample at 180 min. In this patient both the ELISA and gel analysis indicated a rise in serum XLDP, although the results with the two methods were somewhat discrepant, since the gel was most strongly positive for XLDP when the concentration by ELISA was decreasing. To clarify the relationship between the finding of XLDP by gel analysis and the concentration determined by ELISA, the results on all samples were compared. In general, the ELISA results paralleled those obtained by gel analysis (figure 2). The mean concentration in samples with a positive gel for XLDP was 15,003 + 2057 (SE) ng/ml, significantly higher than the level in the samples with a negative gel, 403 ± 74 ng/ml (p < .001). The frequency of positive gels increased progressively in samples with higher XLDP concentrations, from 23% below 100 ng/ml to 100% above 10,000 ng/ml. with XLDP concentrations greater than 1000 ng/ml were associated with a negative gel.
Electrophoretic analysis identified XLDP in at least one serum sample from 27 of 29 patients who achieved reperfusion, but also in five of eight without reperfusion (table 2), indicating that the appearance of serum XLDP was not a specific predictive marker of reperfusion in an individual patient. However, the proportion of samples that were positive after the start of therapy (not shown) in patients with reperfusion was 95 of 146 (65%), significantly higher than that in patients who did not show reperfusion, 23 of 50 (46%) (p < .05). The appearance of XLDP was further correlated with coronary clot lysis, in that XLDP were identified in 53 of 144 (37%) samples taken before reperfusion or in patients never achieving reperfusion, but in 63 of 91 (69%) samples taken after reperfusion (p < .0001) (table 2).
In patients who achieved reperfusion, the time of initial gel identification of XLDP correlated closely with the timing of vascular reperfusion (figure 3). During the 15 min interval immediately before the angiogram documenting reperfusion, 10 of 26 (38%) of patients showed XLDP for the first time, and 12 (46%) showed the new appearance of serum XLDP in the 15 min intervals before and after clot lysis. In nine patients (35%), XLDP appeared more than 15 min before reperfusion and five patients (19%) had the first appearance of serum XLDP more than 15 min after reperfusion.
Similarly, there was a temporal relationship between the elevation of XLDP measured by ELISA and angiographic analysis. Figure 4 shows a rapid rise to a peak concentration at 30 min before lysis that was maintained through the time of reperfusion, followed by a decline to concentrations below 1000 ng/ml by 50 min after reperfusion. However, serum XLDP concentrations did not distinguish between patients who did or did not achieve reperfusion (table 3). In the 29 patients who achieved reperfusion, the mean serum concentration in samples taken after lysis was 10,372 ng/ml, which was not significantly higher than the level before reperfusion, 7370 ng/ml. These concentrations were similar to the mean in samples from patients who did not develop reperfusion, 8422 ng/ml. Also, the mean peak serum 7) showed no FDP and XLDP, while the pretreatment plasma showed a predominant fibrinogen ("monomer") band, bands corresponding to fibrin dimer, trimer, and quadramer, and trace amounts of FDP (fragments Y and D) migrating further than fibrinogen. At 37 min after reperfusion, the plasma fibrinogen had fallen 24% of the baseline concentration and the plasma sample at this time showed heavy bands corresponding to fragments Y and D. The fibrinogen band was little changed, although some conversion to fragment X with a slightly faster mobility may have occurred. In addition, the intensity of the dimer band was markedly decreased, and bands were noted in positions consistent with crosslinked fibrin derivatives XX, XY, and XD. The nonclottable derivatives in the serum sample confirmed the presence of fragments X, Y, and D (FDP) as well as the higher molecular weight of XLDP (XD, XY, XX) noted in the plasma Patient B did not achieve reperfusion of the coronary artery. The electrophoretic patterns of plasma and serum, however, were very similar to those for patient A, who did achieve reperfusion. The pretreatment plasma showed fibrinogen, and fibrin dimer and trimer bands, all of which disappeared during therapy, at the same time that the fibrinogen concentration dropped. The serum showed new bands of both FDP and XLDP during therapy. Therefore similar changes in plasma and serum may occur in patients who develop the lytic state, namely reduction of fibrinogen, fibrin dimer and trimer, and appearance of both FDP and XLDP, whether reperfusion occurs (A) or not (B).
By contrast, XLDP did not appear in the serum of some patients who did not develop a lytic state regardless of whether reperfusion occurred (figure 8). The pretreatment plasma sample from patient C showed fibrinogen and fibrin polymer bands that were un- The association between the appearance of XLDP by gel analysis and the development of a systemic lytic state is reinforced by the temporal correlation between the first appearance of XLDP on gels and the time of decrease in plasma fibrinogen, indicative of the lytic state ( figure 9) . Among the 31 patients in whom this correlation could be made, 19 (61%) had the first appearance of fibrin products in the 15 min interval just before documentation of the systemic lytic state, and in three additional patients this occurred within 15 min after the decrease in plasma fibrinogen. Thus a total of 22 of 31 (71%) patients had the first appearance of XLDP by gel analysis within 15 50,000 mg/ml. 
Discussion
During fibrinolytic therapy for acute myocardial infarction, XLDP were identified by a gel electrophoretic technique and their appearance was correlated temporarily with coronary reperfusion as demonstrated angiographically ( figure 3 ). In addition, a significantly higher proportion of serum samples contained XLDP after reperfusion than before (table 2) . However, the identification of serum XLDP was not a specific marker of clot lysis in individual patients, since five of eight patients without reperfusion also had a positive assay (table 2 BEFORE OR AFTER LYTIC STATE (min) FIGURE 9 . Appearance of XLDP by gel analysis in relation to the time that a systemic lytic state occurred. Zero time indicates the first development of a systemic lytic state, defined as a decrease in plasma fibrinogen concentration below 90% of initial. Patients not included in the analysis include two in whom a systemic lytic state did not develop (see figure 8) and three in whom a lytic state developed but no XLDP were detected. In these latter three patients, the decrease in fibrinogen appeared in only the final sample, to 77%, 84% and 68% of original. radation of plasma fibrin polymers. Considering only 2% of the clottable fibrinogen as fibrin dimer, a fibrinogen concentration of 3 mg/ml, would translate to a plasma dimer concentration of 60,000 ng/ml. Since the fragment DD portion of a fibrin dimer represents about 30% of the total mass, complete plasmatic degradation would generate approximately 18,000 ng/ml of fragment DD. The mean peak concentrations of XLDP measured by ELISA (table 3) are compatible with this value. On the other hand, if the origin of the serum XLDP were from a thrombus, the peak concentration of XLDP in serum would require degradation of approximately 70 mg of crosslinked fibrin, assuming recovery of 75% of its mass as XLDP.4' Assuming a whole blood fibrinogen concentration of 2 mg/ml, this quantity of crosslinked fibrin would require an original volume of 35 ml of whole blood (hematocrit 40%).
Although the fibrin content of coronary artery thrombi is not known, this volume of blood is much larger than that of a coronary artery and thereby also argues against the source of serum XLDP from coronary artery thrombi. Thus, although a test that is specific for XLDP could partly reflect coronary artery thrombolysis, our results indicate that measurement of such unique FDP in the blood by means of sensitive and specific methods of electrophoretic analysis or antibody-specific ELISA is not a reliable indicator for predicting or detecting the success of therapy. The small amount of XLDP derived from coronary artery thrombolysis cannot be detected by the techniques used because of a larger amount originating from other sources during fibrinolytic therapy. Elevations of serum XLDP also may result from degradation of crosslinked fibrin present at unknown or undetected vascular or extravascular sites. However, the studies presented here indicate that elevated serum XLDP may be expected in patients who develop the systemic lytic state, which regularly accompanies streptokinase therapy8 but which also occurs in most patients receiving t-PA9 10 or APSAC'1 12 for the treatment of acute myocardial infarction. Most likely, the XLDP result from degradation of circulating crosslinked fibrin polymers, in parallel with the hyperplasminemic degradation of plasma fibrinogen and independent of the occurrence of vascular reperfusion.
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